Artiva Biotherapeutics, Inc.
NASDAQ:ARTVBiotechnology
-$0.34 today
- Market cap
- $186.36M
- Beta
- 2.40
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$3.53
Volume 0.97M
Average 0.48M
ARTV Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Artiva Biotherapeutics, Inc.NASDAQ: ARTV
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables growth accelerates
Q1 FY2026 accounts payables of $1.81M rose 4319.5% year over year, ahead of the +447.4% change in trailing-twelve-month accounts payables.
Context
- Accounts payables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +4319.5% holds above the trailing-twelve-month pace of +447.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (760K) USD
- Year-over-year change
- -246.4%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (760K) | -246.4% |
| FY2024 | 2024-12-31 | 519K | +227.2% |
| FY2023 | 2023-12-31 | (408K) | -314.7% |
| FY2022 | 2022-12-31 | 190K | +115.3% |
| FY2021 | 2021-12-31 | (1.24M) | — |
Accounts Payables vs competitors
How ARTV compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +447.4% is the highest of 8, against a peer median of -60.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.77M USD | +201.6% | — | — | |
| LTM Mar 2026 | €6.32M EUR | — | +17.8% | 21552.6% | |
| LTM Mar 2026 | $3.13M USD | -534.1% | +26.3% | 3.1% | |
| FY2025 | $1.62M USD | +186.9% | +62.8% | 2534.4% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $1.01M USD | +447.4% | — | — |
| LTM Mar 2026 | $343K USD | -64.3% | -51.8% | 34.3% | |
| LTM Mar 2026 | $233K USD | -91.2% | -54.6% | — | |
| LTM Mar 2026 | $170K USD | -60.6% | — | — | |
| LTM Mar 2026 | $17K USD | +117.0% | — | 0.0% | |
| Peer median (excluding ARTV) | — | -60.6% | +17.8% | 34.3% | |
Competitors are the stored peer set for ARTV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.83M) | (58.79M) | (28.72M) | (65.37M) | (83.87M) |
| Depreciation & Amortization | 248K | 1.16M | 2.27M | 2.43M | 2.6M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.31M | 6.58M | 7.05M | 6.98M | 6.82M |
| Change in Working Capital | 33.41M | (3.87M) | (28.28M) | (325K) | (424K) |
| Accounts Receivables | (468K) | (57K) | (1.23M) | 1.61M | 79K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.24M) | 190K | (408K) | 519K | (760K) |
| Other Working Capital | 35.13M | (4M) | (26.64M) | (2.46M) | 257K |
| Other Non-Cash Items | 18.55M | 4.08M | 251K | 1.26M | (1.88M) |
| Operating Cash Flow | (15.3M) | (50.83M) | (47.43M) | (55.03M) | (76.75M) |
| Capital Expenditures | (1.72M) | (6.3M) | (3.26M) | (642K) | (2.59M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (49.52M) | (176.17M) | (44.88M) |
| Sales of Investments | 0 | 0 | 26.8M | 56.35M | 110.87M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.72M) | (6.3M) | (25.98M) | (120.46M) | 63.41M |
| Debt Repayment | 0 | 0 | 0 | (149K) | (132K) |
| Common Stock Issued | 0 | 0 | 0 | 166.51M | 371K |
| Common Stock Repurchased | 0 | (5K) | (12K) | (4.18M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.86M) | (1.26M) | 24.4M | 51K | (230K) |
| Financing Cash Flow | 152.75M | (1.26M) | 24.39M | 162.23M | 9K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 135.73M | (58.39M) | (49.01M) | (13.27M) | (13.33M) |
| Free Cash Flow | (17.03M) | (57.13M) | (50.69M) | (55.67M) | (79.34M) |
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
Intrinsic Alpha fair value
Locked
Current Price
$3.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.